A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Summary

The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.

Timeline

Start

2021-03-26

Primary completion

2024-03-21

Completion

2024-03-21

Outcome

Outcome not reported

Stopped (Business): “Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns.”

Drugs

Indications